Aqr Capital Management LLC Dynavax Technologies Corp Transaction History

Aqr Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.93 - $17.44 $36,264 - $63,690	-3,652 Reduced 24.85%	11,043 $115,000
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $43,537 - $74,978	-5,844 Reduced 28.45%	14,695 $185,000
Q1 2022 May 16, 2022	SELL	$9.75 - $14.44 $62,838 - $93,065	-6,445 Reduced 23.88%	20,539 $223,000
Q4 2021 Feb 14, 2022	BUY	$13.17 - $20.94 $355,379 - $565,044	26,984 New	26,984 $380,000
Q4 2020 Feb 16, 2021	SELL	$3.73 - $5.6 $102,496 - $153,882	-27,479 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.32 - $11.7 $118,709 - $321,504	27,479 New	27,479 $119,000
Q4 2018 Feb 14, 2019	SELL	$8.14 - $13.28 $162,995 - $265,918	-20,024 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$11.85 - $16.0 $385,587 - $520,624	-32,539 Reduced 61.9%	20,024 $248,000
Q2 2018 Aug 14, 2018	BUY	$15.15 - $20.75 $263,337 - $360,676	17,382 Added 49.41%	52,563 $802,000
Q1 2018 May 15, 2018	SELL	$14.65 - $19.9 $395,007 - $536,563	-26,963 Reduced 43.39%	35,181 $698,000
Q4 2017 Feb 14, 2018	BUY	$17.3 - $24.08 $1.08 Million - $1.5 Million	62,144	62,144 $1.16 Million

275

129M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.57B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.